John S. Kovach, M.D., Chair, Board of Directors and Chief executive officer of Lixte Biotechnology Holdings, Inc, introduced the distribution associated with an IND application into the Food and Drug Administration to execute a Phase I trial of their lead, anti-cancer compound, LB-100.
Dr. Kovach said, "We feel that in fact LB-100, a new anti-cancer compound, stops melanoma cells from declaring themselves against usual types of cancer therapies. In pre-clinical animal types of cancer, LB-100 stops cancer cell growth by itself, but also, it substantially enhances the murder of cancer cells by a number of frequently anti-cancer drugs such as Temozlomide, Doxorubicin, and Docetaxel in addition to radiation.
Here in the initial Phase I trial to become conducted at a country wide recognized comprehensive melanoma center, LB-100 will be tested alone and in mixture by using a standard anti-cancer drug.
No comments:
Post a Comment